

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10560928
	Filing Date		2006-05-05
	First Named Inventor	Yechezkel BARENHOLZ	
	Art Unit	1632	
	Examiner Name	Emily M. Le	
	Attorney Docket Number	BARENHOLZ 13	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

/Agnieszka Boesen/ (10/24/2011)

10/24/2011

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10560928
Filing Date		2006-05-05
First Named Inventor	Yechezkel BARENHOLZ	
Art Unit	1632	
Examiner Name	Emily M. Le	
Attorney Docket Number	BARENHOLZ 13	

1	Alving CR. Liposomes as adjuvants for vaccines. Immunol Rev 1995;145:5–31.	<input type="checkbox"/>
2	Alving CR. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann NY Acad Sci 1995;754:143–52.	<input type="checkbox"/>
3	Babai et al. "A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice" Vaccine 1999;17:1223-38.	<input type="checkbox"/>
4	Babai et al. "A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice" Vaccine 1999;17:1239-50.	<input type="checkbox"/>
5	Cox et al. "Adjuvants—a classification and review of their modes of action" Vaccine 1997;15:248–56.	<input type="checkbox"/>
6	Foged et al. "Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition" Vaccine 2004;22:1903–13.	<input type="checkbox"/>
7	Garbuzenko et al. "Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer" Chem Phys Lipids 2005;135:117–29.	<input type="checkbox"/>
8	Gregoriadis G. "The immunological adjuvant and vaccine carrier properties of liposomes" J Drug Target 1994;2:351–6	<input type="checkbox"/>
9	Israelachvili et al. "Physical principles of membrane organization" Q Rev Biophys 1980;13:121–200.	<input type="checkbox"/>
10	Itskovitz-Cooper et al. "A new intranasal influenza vaccine based on a novel polycationic lipid—ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice" Vaccine 2006;24:3990–4006.	<input type="checkbox"/>
11	Laing et al. "The 'co-delivery' approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates" J Liposome Res 2006;16:229–35.	<input type="checkbox"/>

/Agnieszka Boesen/ (10/24/2011)

10/24/2011

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560928
Filing Date	2006-05-05
First Named Inventor	Yechezkel BARENHOLZ
Art Unit	1632
Examiner Name	Emily M. Le
Attorney Docket Number	BARENHOLZ 13

12	Lonez et al. "Cationic liposomal lipids: from gene carriers to cell signaling" Prog Lipid Res 2008;47:340-7.	<input type="checkbox"/>
13	Miller et al. "Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes" Biochemistry 1998;37:12875-83.	<input type="checkbox"/>
14	Nakanishi et al. "Positively charged liposome functions as an efficient immunoadjuvant in inducing immuneresponses to soluble proteins" Biochem Biophys Res Commun 1997;240:793-7.	<input type="checkbox"/>
15	Perrie et al. "Liposome-mediated DNA vaccination: the effect of vesicle composition" Vaccine 2001;19:3301-10.	<input type="checkbox"/>
16	Schwendener et al. "The effects of charge and size on the interaction of unilamellar liposomes with macrophages" Biochim Biophys Acta 1984;772:93-101.	<input type="checkbox"/>
17	Simberg et al. "DOTAP (and other cationic lipids): chemistry, biophysics, and transfection" Crit Rev Ther Drug Carrier Syst 2004;21(4):257-317.	<input type="checkbox"/>
18	Storm et al. "Liposomes: quo vadis?" Pharm Sci Technol Today 1998;1:19-31.	<input type="checkbox"/>
19	Yan et al. "Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines" Mol Immunol 2007;44:3672-81.	<input type="checkbox"/>
20	Zhou et al. "Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway" Immunomethods 1994;4:229-35. (Abstract Only)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Agnieszka Boesen/ (10/24/2011)	Date Considered	10/24/2011
--------------------	---------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560928
Filing Date	2006-05-05
First Named Inventor	Yechezkel BARENHOLZ
Art Unit	1632
Examiner Name	Emily M. Le
Attorney Docket Number	BARENHOLZ 13

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

/Agnieszka Boesen/ (10/24/2011)

10/24/2011